AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda. PD-L1 inhibitor Imfinzi ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Maria joined AstraZeneca in 2017 as head of Respiratory, Inflammation & Autoimmunity in the Innovative Medicines and Early Development (IMED) Biotech Unit. In her role she leads early-stage ...